Radiomics refers to the systematic extraction and analysis of quantitative features from medical imaging data for integration into computational and artificial intelligence systems. This approach transforms conventional medical images—including computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and ultrasound—into high-dimensional datasets that capture tumor characteristics, tissue properties, and disease patterns beyond what is visually apparent to clinicians ¹⁾.

Radiomics workflows typically involve several key processing stages. Initial image acquisition is followed by image preprocessing, which includes standardization of imaging protocols, noise reduction, and intensity normalization to ensure reproducibility across different scanning conditions and equipment manufacturers. Image segmentation—either manual, semi-automated, or fully automated—delineates regions of interest (ROIs) such as tumors or lesions ²⁾.

Once ROIs are defined, feature extraction algorithms compute hundreds to thousands of quantitative features organized into several categories. First-order statistics capture intensity distributions within the ROI, including mean, median, standard deviation, and histogram-based metrics. Texture features derived from gray-level co-occurrence matrices (GLCM), gray-level run-length matrices (GLRLM), and other mathematical frameworks characterize spatial intensity variations and tissue heterogeneity patterns. Shape and morphologic features describe geometric properties including volume, surface area, sphericity, and compactness. Higher-order features incorporate wavelet transforms, Laplacian-of-Gaussian filters, and deep learning-based representations that capture multiscale information ³⁾.

Dimensionality reduction and feature selection methods address the challenge of high-dimensional feature spaces relative to available training samples, a problem known as the “curse of dimensionality.” Techniques including least absolute shrinkage and selection operator (LASSO), elastic net regularization, and recursive feature elimination identify the most discriminative features while reducing overfitting risk.

Radiomics enables prognostic and predictive modeling across multiple cancer types and disease domains. In oncology, radiomics-based signatures have demonstrated utility for predicting treatment response, identifying patients at risk for disease recurrence, and stratifying patients into risk categories for personalized treatment planning ⁴⁾.

Radiomics also supports differential diagnosis by distinguishing between benign and malignant lesions, characterizing tumor heterogeneity, and identifying imaging biomarkers associated with specific genetic or molecular profiles. This capability enables non-invasive assessment of tumor biology without requiring invasive biopsy procedures.

In multimodal artificial intelligence systems, radiomics features integrate with clinical laboratory values, genomic data, and patient demographics to enhance predictive accuracy. Radiomics outputs function as structured feature matrices that feed into downstream machine learning models, enabling the AI system to incorporate imaging-derived information alongside other data modalities.

Radiomics faces significant reproducibility challenges stemming from variations in imaging protocols, reconstruction algorithms, scanner hardware, and image preprocessing approaches. Two analyses of identical lesions using different imaging parameters may yield substantially different feature values, limiting the generalizability of radiomics models across institutions and equipment manufacturers.

The Imaging Biomarker Standardization Initiative (IBSI) and similar standardization efforts provide guidelines for feature definitions, calculation methodologies, and validation procedures to improve reproducibility. Test-retest studies and phantom validation experiments assess feature stability under varying imaging conditions.

Feature selection and model validation require careful methodology to avoid overfitting. The high dimensionality of radiomics datasets combined with typically small clinical cohorts necessitates rigorous cross-validation strategies, independent external validation cohorts, and permutation testing to establish statistical significance.

Radiomics remains largely in research and early clinical validation phases, with limited adoption in routine clinical workflows. Emerging regulatory pathways, including FDA clearances for specific radiomics-based clinical decision support tools, indicate growing validation of the approach. Integration into electronic health record (EHR) systems and PACS (Picture Archiving and Communication Systems) infrastructure continues to evolve.

The convergence of radiomics with deep learning represents a significant research direction. Rather than hand-crafted feature extraction, end-to-end deep neural networks learn imaging representations directly from raw image data, potentially capturing nonlinear patterns missed by traditional radiomics approaches. This integration positions radiomics as a foundational component of comprehensive multimodal AI architectures in precision medicine and healthcare analytics.

• Imaging-Derived Features and Vector Search
• Early Fusion vs Late Fusion
• Precision Oncology Workflow